Simon Kraler and Colleagues’ New Work on JCAD: Targeting Impaired Fibrinolysis to Address Post-ACS Residual Risk
Simon Kraler, ESC Young Cardiovascular Professionals Committee Member at European Society of Cardiology, posted on LinkedIn:
“Residual risk: is it time to move beyond LDL-c and inflammation?
Despite guideline-directed lipid lowering and anti-inflammatory therapy, patients with a recent ACS remain at 𝐯𝐞𝐫𝐲 𝐡𝐢𝐠𝐡 𝐢𝐬𝐜𝐡𝐚𝐞𝐦𝐢𝐜 𝐫𝐢𝐬𝐤.
Based on GWAS and mechanistic data, we hypothesized that JCAD (‘Junctional Protein Associated with Coronary Artery Disease’) on chromosome 10 might represent the missing link.
In our newly published European Heart Journal study, JCAD independently predicted 1-year MACE in patients with residual lipid risk, inflammatory risk, or both – notably independent of LDL-c and hs-CRP
JCAD = impaired endogenous fibrinolysis and high MACE risk, with similar results obtained during external validation.
JCAD may represent a novel therapeutic target to address residual risk after a recent ACS.
Title: The junctional protein associated with coronary artery disease predicts adverse cardiovascular events in patients with acute coronary syndromes at high residual risk
Authors: Simon Kraler, Luca Liberale, Amedeo Tirandi, Margherita Moriero, Yifan Wang, Mohamed Farag, Federico Carbone, Maria B Bertolotto, Valentina Pusterla, Davide Ramoni, Stefano Ministrini, Yustina M Puspitasari, Francesco Bruno, Lorenz Räber, Davide Di Vece, Christian Templin, Olivier Muller, François Mach, Filippo Crea, Giovanni G Camici, Tetiana Lapikova-Bryhinska, Alexander Akhmedov, Arnold von Eckardstein, Diana A Gorog, Fabrizio Montecucco, Thomas F Lüscher
Special thanks to the colleagues and friends at University of Genoa, King’s College London, University of Zurich, CHUV | Lausanne university hospital, Universitätsspital Zürich, HUG – Hopitaux Universitaires de Genève and Insel Gruppe.
Thank you Thomas F. Lüscher, Luca Liberale, Giovanni G Camici, Diana Gorog, Lorenz Räber, Davide Di Vece, Yifan Wang, Francesco Bruno and all!”
Discover the latest in Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia